

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Both Sexes, 18 SEER Areas, 2009-2011

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	40.37	( 40.28, 40.46 )	40.55	( 40.46, 40.65 )	37.63	( 37.37, 37.89 )
Invasive and In Situ	42.73	( 42.64, 42.82 )	42.91	( 42.81, 43.01 )	38.95	( 38.69, 39.22 )
Oral Cavity and Pharynx	1.10	( 1.09, 1.11 )	1.15	( 1.13, 1.16 )	0.80	( 0.76, 0.83 )
Esophagus	0.50	( 0.50, 0.51 )	0.53	( 0.52, 0.54 )	0.45	( 0.42, 0.48 )
Stomach	0.87	( 0.85, 0.88 )	0.76	( 0.75, 0.78 )	1.10	( 1.06, 1.15 )
Colon and Rectum	4.66	( 4.63, 4.69 )	4.56	( 4.53, 4.59 )	4.85	( 4.75, 4.94 )
Invasive and In Situ	4.83	( 4.80, 4.86 )	4.72	( 4.68, 4.75 )	5.07	( 4.97, 5.17 )
Liver and Intrahepatic Bile Duct	0.89	( 0.88, 0.90 )	0.79	( 0.77, 0.80 )	0.91	( 0.88, 0.95 )
Pancreas	1.50	( 1.49, 1.52 )	1.49	( 1.47, 1.51 )	1.59	( 1.54, 1.65 )
Larynx	0.35	( 0.35, 0.36 )	0.36	( 0.35, 0.37 )	0.44	( 0.41, 0.47 )
Invasive and In Situ	0.38	( 0.37, 0.39 )	0.38	( 0.38, 0.39 )	0.47	( 0.44, 0.50 )
Lung and Bronchus	6.75	( 6.71, 6.79 )	6.92	( 6.88, 6.96 )	6.47	( 6.36, 6.58 )
Melanoma of the Skin	2.05	( 2.03, 2.07 )	2.39	( 2.36, 2.41 )	0.09	( 0.08, 0.11 )
Invasive and In Situ	3.44	( 3.42, 3.47 )	3.90	( 3.87, 3.93 )	0.12	( 0.11, 0.14 )
Breast	6.38	( 6.35, 6.42 )	6.50	( 6.47, 6.54 )	5.88	( 5.79, 5.98 )
Invasive and In Situ	7.62	( 7.58, 7.65 )	7.73	( 7.69, 7.77 )	7.05	( 6.94, 7.15 )
Urinary Bladder (Invasive and In Situ)	2.40	( 2.38, 2.43 )	2.60	( 2.58, 2.63 )	1.25	( 1.20, 1.30 )
Kidney and Renal Pelvis	1.60	( 1.59, 1.62 )	1.65	( 1.63, 1.67 )	1.60	( 1.55, 1.65 )
Brain and Other Nervous System	0.62	( 0.61, 0.63 )	0.68	( 0.67, 0.69 )	0.35	( 0.32, 0.37 )
Thyroid	1.13	( 1.11, 1.14 )	1.18	( 1.17, 1.20 )	0.64	( 0.62, 0.67 )
Hodgkin Lymphoma	0.22	( 0.22, 0.23 )	0.24	( 0.23, 0.24 )	0.19	( 0.18, 0.21 )
Non-Hodgkin Lymphoma	2.12	( 2.11, 2.14 )	2.22	( 2.20, 2.25 )	1.28	( 1.24, 1.33 )
Myeloma	0.72	( 0.71, 0.73 )	0.66	( 0.65, 0.67 )	1.21	( 1.17, 1.26 )
Leukemia	1.43	( 1.42, 1.45 )	1.50	( 1.48, 1.51 )	0.96	( 0.92, 1.01 )
Acute Lymphocytic Leukemia	0.13	( 0.13, 0.14 )	0.14	( 0.14, 0.15 )	0.07	( 0.07, 0.08 )
Chronic Lymphocytic Leukemia	0.54	( 0.53, 0.55 )	0.57	( 0.56, 0.58 )	0.32	( 0.29, 0.35 )
Acute Myeloid Leukemia	0.43	( 0.42, 0.44 )	0.45	( 0.44, 0.46 )	0.31	( 0.29, 0.34 )
Chronic Myeloid Leukemia	0.18	( 0.18, 0.19 )	0.18	( 0.18, 0.19 )	0.14	( 0.13, 0.16 )
Kaposi Sarcoma	0.05	( 0.04, 0.05 )	0.04	( 0.04, 0.04 )	0.08	( 0.07, 0.09 )
Mesothelioma	0.12	( 0.12, 0.13 )	0.14	( 0.13, 0.15 )	0.06	( 0.05, 0.07 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 18 SEER Areas, 2009-2011

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	34.75 ( 34.40, 35.11 )	29.15 ( 27.99, 30.41 )	37.15 ( 36.83, 37.47 )
Invasive and In Situ	36.13 ( 35.77, 36.48 )	29.95 ( 28.77, 31.21 )	38.36 ( 38.04, 38.69 )
Oral Cavity and Pharynx	0.88 ( 0.83, 0.94 )	0.80 ( 0.65, 1.08 )	0.81 ( 0.76, 0.86 )
Esophagus	0.34 ( 0.30, 0.39 )	0.32 ( 0.21, 0.56 )	0.38 ( 0.34, 0.41 )
Stomach	1.78 ( 1.69, 1.87 )	1.07 ( 0.86, 1.40 )	1.49 ( 1.43, 1.57 )
Colon and Rectum	4.99 ( 4.85, 5.14 )	4.23 ( 3.79, 4.77 )	4.56 ( 4.44, 4.68 )
Invasive and In Situ	5.17 ( 5.03, 5.31 )	4.33 ( 3.89, 4.88 )	4.70 ( 4.58, 4.82 )
Liver and Intrahepatic Bile Duct	1.92 ( 1.84, 2.01 )	1.47 ( 1.24, 1.81 )	1.59 ( 1.53, 1.66 )
Pancreas	1.58 ( 1.50, 1.67 )	1.23 ( 0.99, 1.58 )	1.64 ( 1.57, 1.72 )
Larynx	0.18 ( 0.16, 0.21 )	0.25 ( 0.16, 0.48 )	0.30 ( 0.27, 0.33 )
Invasive and In Situ	0.19 ( 0.17, 0.22 )	0.26 ( 0.17, 0.49 )	0.31 ( 0.29, 0.35 )
Lung and Bronchus	5.55 ( 5.41, 5.70 )	4.46 ( 4.00, 5.01 )	4.28 ( 4.17, 4.40 )
Melanoma of the Skin	0.18 ( 0.15, 0.22 )	0.38 ( 0.28, 0.61 )	0.49 ( 0.46, 0.54 )
Invasive and In Situ	0.24 ( 0.21, 0.28 )	0.59 ( 0.45, 0.85 )	0.78 ( 0.73, 0.83 )
Breast	5.38 ( 5.27, 5.50 )	4.06 ( 3.68, 4.54 )	5.12 ( 5.01, 5.23 )
Invasive and In Situ	6.67 ( 6.55, 6.80 )	4.60 ( 4.20, 5.09 )	5.99 ( 5.88, 6.10 )
Urinary Bladder (Invasive and In Situ)	1.40 ( 1.33, 1.49 )	0.93 ( 0.71, 1.28 )	1.64 ( 1.56, 1.72 )
Kidney and Renal Pelvis	1.03 ( 0.97, 1.09 )	1.96 ( 1.71, 2.31 )	1.75 ( 1.69, 1.82 )
Brain and Other Nervous System	0.39 ( 0.36, 0.43 )	0.30 ( 0.18, 0.57 )	0.54 ( 0.51, 0.58 )
Thyroid	1.21 ( 1.16, 1.27 )	0.75 ( 0.59, 1.04 )	1.04 ( 1.01, 1.09 )
Hodgkin Lymphoma	0.12 ( 0.10, 0.14 )	0.09 ( 0.05, 0.30 )	0.21 ( 0.20, 0.24 )
Non-Hodgkin Lymphoma	1.83 ( 1.75, 1.92 )	1.33 ( 1.10, 1.68 )	2.23 ( 2.16, 2.31 )
Myeloma	0.54 ( 0.50, 0.59 )	0.44 ( 0.31, 0.71 )	0.76 ( 0.72, 0.81 )
Leukemia	0.96 ( 0.90, 1.02 )	0.78 ( 0.60, 1.07 )	1.21 ( 1.15, 1.27 )
Acute Lymphocytic Leukemia	0.10 ( 0.09, 0.12 )	0.09 ( 0.06, 0.30 )	0.19 ( 0.18, 0.21 )
Chronic Lymphocytic Leukemia	0.17 ( 0.14, 0.20 )	0.18 ( 0.10, 0.43 )	0.30 ( 0.27, 0.33 )
Acute Myeloid Leukemia	0.43 ( 0.39, 0.47 )	0.26 ( 0.16, 0.51 )	0.41 ( 0.38, 0.45 )
Chronic Myeloid Leukemia	0.15 ( 0.13, 0.18 )	0.10 ( 0.06, 0.31 )	0.18 ( 0.15, 0.21 )
Kaposi Sarcoma	0.02 ( 0.01, 0.03 )	0.02 ( 0.00, 0.24 )	0.09 ( 0.07, 0.11 )
Mesothelioma	0.06 ( 0.04, 0.08 )	0.06 ( 0.01, 0.29 )	0.11 ( 0.10, 0.14 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 18 SEER Areas, 2009-2011

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	43.31	( 43.17, 43.44 )	42.90	( 42.75, 43.04 )	41.63	( 41.22, 42.04 )
Invasive and In Situ	44.76	( 44.63, 44.90 )	44.34	( 44.19, 44.49 )	41.96	( 41.55, 42.37 )
Oral Cavity and Pharynx	1.55	( 1.52, 1.57 )	1.61	( 1.58, 1.63 )	1.15	( 1.09, 1.22 )
Esophagus	0.80	( 0.78, 0.82 )	0.85	( 0.83, 0.87 )	0.63	( 0.59, 0.69 )
Stomach	1.08	( 1.06, 1.11 )	0.98	( 0.96, 1.01 )	1.23	( 1.16, 1.31 )
Colon and Rectum	4.84	( 4.80, 4.89 )	4.73	( 4.69, 4.78 )	4.93	( 4.79, 5.07 )
Invasive and In Situ	5.03	( 4.99, 5.08 )	4.91	( 4.86, 4.96 )	5.17	( 5.03, 5.32 )
Liver and Intrahepatic Bile Duct	1.27	( 1.25, 1.29 )	1.13	( 1.10, 1.15 )	1.36	( 1.30, 1.43 )
Pancreas	1.52	( 1.50, 1.55 )	1.52	( 1.49, 1.55 )	1.51	( 1.43, 1.59 )
Larynx	0.59	( 0.58, 0.61 )	0.59	( 0.58, 0.61 )	0.75	( 0.70, 0.81 )
Invasive and In Situ	0.64	( 0.62, 0.65 )	0.64	( 0.62, 0.65 )	0.80	( 0.75, 0.86 )
Lung and Bronchus	7.43	( 7.38, 7.49 )	7.46	( 7.40, 7.52 )	7.78	( 7.60, 7.96 )
Melanoma of the Skin	2.56	( 2.53, 2.59 )	2.95	( 2.91, 2.99 )	0.08	( 0.06, 0.11 )
Invasive and In Situ	4.26	( 4.22, 4.30 )	4.77	( 4.72, 4.82 )	0.11	( 0.09, 0.14 )
Breast	0.13	( 0.12, 0.14 )	0.13	( 0.12, 0.14 )	0.15	( 0.12, 0.18 )
Invasive and In Situ	0.14	( 0.14, 0.15 )	0.14	( 0.13, 0.15 )	0.17	( 0.14, 0.20 )
Prostate	15.02	( 14.95, 15.10 )	14.16	( 14.08, 14.24 )	19.08	( 18.82, 19.35 )
Testis	0.38	( 0.37, 0.39 )	0.46	( 0.45, 0.47 )	0.09	( 0.08, 0.11 )
Urinary Bladder (Invasive and In Situ)	3.83	( 3.79, 3.87 )	4.15	( 4.10, 4.19 )	1.79	( 1.70, 1.89 )
Kidney and Renal Pelvis	2.04	( 2.02, 2.07 )	2.10	( 2.07, 2.13 )	1.94	( 1.86, 2.03 )
Brain and Other Nervous System	0.69	( 0.67, 0.71 )	0.76	( 0.74, 0.78 )	0.36	( 0.33, 0.40 )
Thyroid	0.57	( 0.56, 0.59 )	0.61	( 0.60, 0.63 )	0.26	( 0.23, 0.29 )
Hodgkin Lymphoma	0.24	( 0.23, 0.25 )	0.26	( 0.25, 0.27 )	0.21	( 0.19, 0.24 )
Non-Hodgkin Lymphoma	2.36	( 2.33, 2.39 )	2.46	( 2.43, 2.50 )	1.41	( 1.34, 1.49 )
Myeloma	0.83	( 0.81, 0.85 )	0.78	( 0.76, 0.80 )	1.25	( 1.18, 1.33 )
Leukemia	1.70	( 1.67, 1.72 )	1.77	( 1.74, 1.80 )	1.07	( 1.00, 1.14 )
Acute Lymphocytic Leukemia	0.14	( 0.14, 0.15 )	0.16	( 0.15, 0.17 )	0.08	( 0.07, 0.10 )
Chronic Lymphocytic Leukemia	0.66	( 0.65, 0.68 )	0.70	( 0.68, 0.71 )	0.37	( 0.33, 0.42 )
Acute Myeloid Leukemia	0.49	( 0.48, 0.51 )	0.51	( 0.50, 0.53 )	0.34	( 0.30, 0.38 )
Chronic Myeloid Leukemia	0.22	( 0.21, 0.23 )	0.22	( 0.21, 0.23 )	0.15	( 0.13, 0.18 )
Kaposi Sarcoma	0.08	( 0.07, 0.08 )	0.07	( 0.06, 0.07 )	0.14	( 0.12, 0.16 )
Mesothelioma	0.21	( 0.20, 0.22 )	0.23	( 0.22, 0.24 )	0.10	( 0.08, 0.13 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Males, 18 SEER Areas, 2009-2011

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	36.92 ( 36.39, 37.47 )	29.98 ( 28.29, 31.89 )	40.34 ( 39.85, 40.85 )
Invasive and In Situ	37.26 ( 36.72, 37.81 )	30.25 ( 28.55, 32.16 )	40.78 ( 40.28, 41.29 )
Oral Cavity and Pharynx	1.25 ( 1.16, 1.36 )	1.24 ( 0.96, 1.81 )	1.12 ( 1.04, 1.21 )
Esophagus	0.53 ( 0.47, 0.62 )	0.49 ( 0.30, 1.03 )	0.61 ( 0.56, 0.68 )
Stomach	2.11 ( 1.97, 2.26 )	1.36 ( 0.99, 2.01 )	1.80 ( 1.70, 1.93 )
Colon and Rectum	5.33 ( 5.13, 5.54 )	4.62 ( 3.96, 5.52 )	4.92 ( 4.75, 5.11 )
Invasive and In Situ	5.53 ( 5.32, 5.74 )	4.73 ( 4.07, 5.64 )	5.08 ( 4.90, 5.26 )
Liver and Intrahepatic Bile Duct	2.66 ( 2.53, 2.80 )	2.09 ( 1.69, 2.76 )	2.21 ( 2.11, 2.33 )
Pancreas	1.56 ( 1.45, 1.69 )	1.28 ( 0.98, 1.87 )	1.55 ( 1.45, 1.66 )
Larynx	0.35 ( 0.30, 0.41 )	0.40 ( 0.25, 0.90 )	0.56 ( 0.51, 0.64 )
Invasive and In Situ	0.37 ( 0.32, 0.44 )	0.41 ( 0.25, 0.91 )	0.59 ( 0.54, 0.66 )
Lung and Bronchus	6.83 ( 6.59, 7.09 )	4.89 ( 4.21, 5.81 )	4.96 ( 4.77, 5.17 )
Melanoma of the Skin	0.21 ( 0.17, 0.28 )	0.39 ( 0.24, 0.89 )	0.49 ( 0.44, 0.55 )
Invasive and In Situ	0.29 ( 0.24, 0.36 )	0.57 ( 0.38, 1.08 )	0.78 ( 0.71, 0.87 )
Breast	0.09 ( 0.07, 0.14 )	0.02 ( 0.00, 0.52 )	0.07 ( 0.06, 0.11 )
Invasive and In Situ	0.10 ( 0.07, 0.15 )	0.03 ( 0.01, 0.53 )	0.08 ( 0.06, 0.12 )
Prostate	10.10 ( 9.84, 10.37 )	7.01 ( 6.25, 8.01 )	14.03 ( 13.76, 14.31 )
Testis	0.14 ( 0.12, 0.18 )	0.34 ( 0.25, 0.79 )	0.35 ( 0.33, 0.39 )
Urinary Bladder (Invasive and In Situ)	2.23 ( 2.09, 2.39 )	1.64 ( 1.18, 2.38 )	2.65 ( 2.50, 2.81 )
Kidney and Renal Pelvis	1.37 ( 1.27, 1.47 )	2.43 ( 2.03, 3.08 )	2.19 ( 2.08, 2.30 )
Brain and Other Nervous System	0.45 ( 0.40, 0.52 )	0.28 ( 0.19, 0.75 )	0.55 ( 0.51, 0.61 )
Thyroid	0.58 ( 0.53, 0.65 )	0.35 ( 0.23, 0.82 )	0.46 ( 0.42, 0.51 )
Hodgkin Lymphoma	0.13 ( 0.11, 0.17 )	0.09 ( 0.04, 0.57 )	0.24 ( 0.21, 0.29 )
Non-Hodgkin Lymphoma	2.06 ( 1.93, 2.19 )	1.36 ( 1.06, 1.94 )	2.39 ( 2.28, 2.52 )
Myeloma	0.63 ( 0.56, 0.71 )	0.48 ( 0.28, 1.02 )	0.88 ( 0.80, 0.97 )
Leukemia	1.17 ( 1.08, 1.27 )	0.84 ( 0.58, 1.40 )	1.37 ( 1.28, 1.47 )
Acute Lymphocytic Leukemia	0.12 ( 0.10, 0.16 )	0.09 ( 0.04, 0.57 )	0.19 ( 0.17, 0.23 )
Chronic Lymphocytic Leukemia	0.23 ( 0.19, 0.29 )	0.21 ( 0.08, 0.73 )	0.35 ( 0.30, 0.42 )
Acute Myeloid Leukemia	0.49 ( 0.44, 0.57 )	0.22 ( 0.11, 0.71 )	0.45 ( 0.41, 0.52 )
Chronic Myeloid Leukemia	0.21 ( 0.17, 0.26 )	0.08 ( 0.03, 0.57 )	0.20 ( 0.17, 0.26 )
Kaposi Sarcoma	0.04 ( 0.02, 0.07 )	0.04 ( 0.00, 0.54 )	0.12 ( 0.10, 0.16 )
Mesothelioma	0.10 ( 0.07, 0.15 )	0.08 ( 0.01, 0.59 )	0.19 ( 0.16, 0.24 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Females, 18 SEER Areas, 2009-2011

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	37.81	( 37.70, 37.93 )	38.53	( 38.40, 38.67 )	34.18	( 33.84, 34.53 )
Invasive and In Situ	41.08	( 40.96, 41.20 )	41.83	( 41.69, 41.97 )	36.42	( 36.08, 36.77 )
Oral Cavity and Pharynx	0.67	( 0.66, 0.69 )	0.70	( 0.68, 0.72 )	0.48	( 0.45, 0.52 )
Esophagus	0.23	( 0.22, 0.24 )	0.23	( 0.22, 0.24 )	0.28	( 0.25, 0.32 )
Stomach	0.67	( 0.65, 0.69 )	0.56	( 0.54, 0.57 )	1.00	( 0.94, 1.07 )
Colon and Rectum	4.49	( 4.45, 4.53 )	4.40	( 4.35, 4.44 )	4.79	( 4.66, 4.92 )
Invasive and In Situ	4.64	( 4.60, 4.69 )	4.54	( 4.49, 4.58 )	4.99	( 4.86, 5.12 )
Liver and Intrahepatic Bile Duct	0.53	( 0.51, 0.54 )	0.46	( 0.44, 0.47 )	0.51	( 0.47, 0.55 )
Pancreas	1.48	( 1.46, 1.51 )	1.45	( 1.43, 1.48 )	1.66	( 1.58, 1.74 )
Larynx	0.13	( 0.13, 0.14 )	0.14	( 0.13, 0.15 )	0.17	( 0.14, 0.19 )
Invasive and In Situ	0.14	( 0.13, 0.15 )	0.15	( 0.14, 0.16 )	0.17	( 0.15, 0.20 )
Lung and Bronchus	6.17	( 6.12, 6.22 )	6.46	( 6.41, 6.52 )	5.39	( 5.26, 5.53 )
Melanoma of the Skin	1.61	( 1.58, 1.63 )	1.89	( 1.86, 1.91 )	0.10	( 0.09, 0.13 )
Invasive and In Situ	2.74	( 2.71, 2.77 )	3.13	( 3.09, 3.17 )	0.13	( 0.11, 0.15 )
Breast	12.33	( 12.27, 12.40 )	12.70	( 12.63, 12.77 )	10.99	( 10.82, 11.18 )
Invasive and In Situ	14.75	( 14.68, 14.82 )	15.13	( 15.05, 15.20 )	13.19	( 13.00, 13.39 )
Cervix Uteri	0.65	( 0.63, 0.66 )	0.64	( 0.62, 0.65 )	0.78	( 0.73, 0.82 )
Corpus and Uterus, NOS	2.73	( 2.71, 2.76 )	2.81	( 2.78, 2.85 )	2.48	( 2.39, 2.57 )
Invasive and In Situ	2.76	( 2.73, 2.79 )	2.84	( 2.80, 2.87 )	2.51	( 2.42, 2.60 )
Ovary <sup>a</sup>	1.33	( 1.31, 1.35 )	1.41	( 1.38, 1.43 )	0.99	( 0.93, 1.05 )
Urinary Bladder (Invasive and In Situ)	1.14	( 1.12, 1.16 )	1.21	( 1.19, 1.24 )	0.81	( 0.76, 0.87 )
Kidney and Renal Pelvis	1.19	( 1.17, 1.21 )	1.23	( 1.20, 1.25 )	1.29	( 1.23, 1.36 )
Brain and Other Nervous System	0.55	( 0.54, 0.56 )	0.60	( 0.59, 0.62 )	0.34	( 0.31, 0.37 )
Thyroid	1.68	( 1.66, 1.70 )	1.77	( 1.75, 1.80 )	1.00	( 0.95, 1.05 )
Hodgkin Lymphoma	0.20	( 0.19, 0.21 )	0.22	( 0.21, 0.22 )	0.18	( 0.16, 0.20 )
Non-Hodgkin Lymphoma	1.91	( 1.89, 1.94 )	2.01	( 1.98, 2.04 )	1.17	( 1.11, 1.23 )
Myeloma	0.62	( 0.61, 0.64 )	0.55	( 0.53, 0.57 )	1.19	( 1.12, 1.25 )
Leukemia	1.19	( 1.17, 1.22 )	1.24	( 1.22, 1.27 )	0.87	( 0.82, 0.93 )
Acute Lymphocytic Leukemia	0.12	( 0.11, 0.12 )	0.13	( 0.12, 0.14 )	0.07	( 0.06, 0.09 )
Chronic Lymphocytic Leukemia	0.43	( 0.42, 0.44 )	0.45	( 0.44, 0.47 )	0.27	( 0.24, 0.31 )
Acute Myeloid Leukemia	0.38	( 0.37, 0.39 )	0.39	( 0.38, 0.40 )	0.29	( 0.26, 0.33 )
Chronic Myeloid Leukemia	0.15	( 0.14, 0.15 )	0.15	( 0.14, 0.16 )	0.13	( 0.11, 0.16 )
Kaposi Sarcoma	0.01	( 0.01, 0.02 )	0.01	( 0.01, 0.02 )	0.01	( 0.01, 0.02 )
Mesothelioma	0.05	( 0.05, 0.06 )	0.06	( 0.05, 0.06 )	0.03	( 0.02, 0.04 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Females, 18 SEER Areas, 2009-2011

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	33.08 ( 32.62, 33.55 )	28.63 ( 27.02, 30.41 )	34.72 ( 34.30, 35.14 )
Invasive and In Situ	35.36 ( 34.89, 35.84 )	29.94 ( 28.32, 31.74 )	36.68 ( 36.26, 37.12 )
Oral Cavity and Pharynx	0.56 ( 0.50, 0.63 )	0.40 ( 0.27, 0.81 )	0.54 ( 0.48, 0.60 )
Esophagus	0.18 ( 0.14, 0.24 )	0.16 ( 0.08, 0.56 )	0.17 ( 0.14, 0.21 )
Stomach	1.50 ( 1.39, 1.63 )	0.84 ( 0.60, 1.31 )	1.23 ( 1.15, 1.33 )
Colon and Rectum	4.71 ( 4.51, 4.91 )	3.89 ( 3.29, 4.68 )	4.24 ( 4.08, 4.41 )
Invasive and In Situ	4.86 ( 4.67, 5.07 )	3.98 ( 3.38, 4.78 )	4.38 ( 4.22, 4.55 )
Liver and Intrahepatic Bile Duct	1.30 ( 1.20, 1.41 )	0.90 ( 0.66, 1.39 )	1.03 ( 0.96, 1.11 )
Pancreas	1.60 ( 1.49, 1.72 )	1.17 ( 0.83, 1.74 )	1.71 ( 1.60, 1.83 )
Larynx	0.04 ( 0.03, 0.07 )	0.11 ( 0.04, 0.50 )	0.07 ( 0.05, 0.10 )
Invasive and In Situ	0.04 ( 0.03, 0.07 )	0.12 ( 0.05, 0.52 )	0.07 ( 0.06, 0.10 )
Lung and Bronchus	4.50 ( 4.33, 4.69 )	4.11 ( 3.50, 4.91 )	3.75 ( 3.60, 3.90 )
Melanoma of the Skin	0.15 ( 0.12, 0.20 )	0.37 ( 0.24, 0.77 )	0.50 ( 0.45, 0.57 )
Invasive and In Situ	0.20 ( 0.17, 0.26 )	0.61 ( 0.42, 1.05 )	0.79 ( 0.72, 0.86 )
Breast	9.93 ( 9.72, 10.15 )	7.92 ( 7.18, 8.83 )	9.76 ( 9.56, 9.96 )
Invasive and In Situ	12.33 ( 12.11, 12.58 )	8.97 ( 8.21, 9.91 )	11.45 ( 11.24, 11.66 )
Cervix Uteri	0.65 ( 0.59, 0.72 )	0.60 ( 0.45, 1.00 )	0.91 ( 0.86, 0.98 )
Corpus and Uterus, NOS	2.16 ( 2.07, 2.27 )	2.05 ( 1.75, 2.57 )	2.34 ( 2.26, 2.44 )
Invasive and In Situ	2.18 ( 2.08, 2.28 )	2.07 ( 1.76, 2.59 )	2.36 ( 2.27, 2.46 )
Ovary <sup>c</sup>	1.03 ( 0.96, 1.12 )	1.13 ( 0.82, 1.68 )	1.26 ( 1.18, 1.34 )
Urinary Bladder (Invasive and In Situ)	0.72 ( 0.64, 0.82 )	0.32 ( 0.17, 0.75 )	0.80 ( 0.73, 0.89 )
Kidney and Renal Pelvis	0.74 ( 0.67, 0.82 )	1.51 ( 1.22, 2.03 )	1.38 ( 1.30, 1.46 )
Brain and Other Nervous System	0.34 ( 0.30, 0.40 )	0.31 ( 0.12, 0.81 )	0.52 ( 0.47, 0.58 )
Thyroid	1.77 ( 1.69, 1.86 )	1.15 ( 0.85, 1.67 )	1.62 ( 1.56, 1.70 )
Hodgkin Lymphoma	0.11 ( 0.09, 0.14 )	0.10 ( 0.04, 0.49 )	0.19 ( 0.17, 0.23 )
Non-Hodgkin Lymphoma	1.64 ( 1.54, 1.75 )	1.31 ( 0.97, 1.87 )	2.10 ( 1.99, 2.21 )
Myeloma	0.46 ( 0.41, 0.53 )	0.41 ( 0.24, 0.85 )	0.67 ( 0.61, 0.74 )
Leukemia	0.78 ( 0.71, 0.86 )	0.73 ( 0.50, 1.20 )	1.07 ( 1.00, 1.15 )
Acute Lymphocytic Leukemia	0.09 ( 0.07, 0.12 )	0.10 ( 0.05, 0.49 )	0.18 ( 0.16, 0.21 )
Chronic Lymphocytic Leukemia	0.11 ( 0.09, 0.15 )	0.16 ( 0.06, 0.58 )	0.25 ( 0.21, 0.30 )
Acute Myeloid Leukemia	0.37 ( 0.33, 0.43 )	0.30 ( 0.15, 0.73 )	0.37 ( 0.33, 0.43 )
Chronic Myeloid Leukemia	0.10 ( 0.08, 0.14 )	0.11 ( 0.06, 0.50 )	0.15 ( 0.12, 0.20 )
Kaposi Sarcoma	0.00 ( 0.00, 0.03 )	0.01 ( 0.00, 0.42 )	0.05 ( 0.03, 0.08 )
Mesothelioma	0.02 ( 0.01, 0.05 )	0.04 ( 0.00, 0.45 )	0.05 ( 0.04, 0.08 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>c</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.